Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACO/ARO/AIO-18.2 in locally advanced rectal adenocarcinoma
2018-001356-35Phase 3Active
- Sponsor
- Heidelberg University
- Start
- May 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, oxaliplatin, folinic acid and capecitabine in rectal adenocarcinoma and rectal cancer (2 arms), sponsored by Heidelberg University. Primary endpoint: Disease-free survival. Started May 2020; status: active.
02
Drugs
fluorouraciloxaliplatinfolinic acidcapecitabine
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on 2018-001356-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001356-35.